L N Shulman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?
    L N Shulman
    Dana Farber Cancer Institute Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 3:523-8. 2001
  2. ncbi Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion
    J P Eder
    Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
    Clin Cancer Res 4:317-24. 1998
  3. ncbi Skin recurrences after breast-conserving therapy for early-stage breast cancer
    I Gage
    Joint Center for Radiation Therapy, Boston, MA, USA
    J Clin Oncol 16:480-6. 1998
  4. ncbi Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    H J Burstein
    Division of Adult Oncology and Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:2722-30. 2001
  5. ncbi Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies
    C A Bunnell
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 48:347-55. 2001
  6. ncbi Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up
    G P Canellos
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 14:268-72. 2003
  7. ncbi Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment
    D Smith
    Department of Radiology, Brigham and Women s Hospital, Boston, Mass 02155, USA
    Oncology 55:284-8. 1998

Detail Information

Publications7

  1. ncbi What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?
    L N Shulman
    Dana Farber Cancer Institute Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 3:523-8. 2001
    ..The reasons for this uncertainty and lack of clarity are complex, and they are addressed in this review...
  2. ncbi Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion
    J P Eder
    Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
    Clin Cancer Res 4:317-24. 1998
    ..The dosing regimen recommended for Phase II trials of the 9AC CD formulation is 54.2 micrograms/m2/h, given as a 72-h continuous i.v. infusion every 3 weeks...
  3. ncbi Skin recurrences after breast-conserving therapy for early-stage breast cancer
    I Gage
    Joint Center for Radiation Therapy, Boston, MA, USA
    J Clin Oncol 16:480-6. 1998
    ..To assess the frequency and prognosis of skin recurrences after breast-conserving therapy (BCT) compared with other breast recurrences...
  4. ncbi Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    H J Burstein
    Division of Adult Oncology and Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:2722-30. 2001
    ..CONCLUSION: Trastuzumab in combination with vinorelbine is highly active in women with HER2-overexpressing advanced breast cancer and is well tolerated...
  5. ncbi Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies
    C A Bunnell
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 48:347-55. 2001
    ..This study sought to determine the maximum tolerated dose and principal toxicities of this agent and to characterize its pharmacokinetic behavior...
  6. ncbi Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up
    G P Canellos
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 14:268-72. 2003
    ..The EVA regimen (etoposide, vinblastine, doxorubicin) is an attempt to substitute a known active agent, etoposide, for bleomycin and dacarbazine...
  7. ncbi Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment
    D Smith
    Department of Radiology, Brigham and Women s Hospital, Boston, Mass 02155, USA
    Oncology 55:284-8. 1998
    ..Computed tomography (CT) has become an integral part of the evaluation of these patients at presentation and after completion of therapy. The purpose of this study is to identify CT features that predict increased risk of relapse...